雅各臣科研制药(02633.HK)将加大亚洲市场销售
雅各臣科研制药(02633.HK)首席商务官黄一伟在传媒午宴上表示,公司除了发展香港本地市场外,未来希望继续於亚洲最大化产品组合价值,包括大中华、南亚及北亚三个市场。在进入较大的东南亚市场,例如韩国、泰国及日本时会在当地寻找合作夥伴,市场较小的则会采取与分销商合作。目前公司有93%的收入来自本地,7%来自其他亚洲地区,期望未来三年间,来自香港的收入占比会下降至80至85%,其他亚洲地区的占比则上升至15%。
公司已提交了61份非专利药申请,当中14份已获批准,预计今年将获得25份以上的批准。今年来,参与了11项香港的招标项目。他预期,获批的非专利药将会在2020年第二季起迎来收成期。除此之外,公司亦会开发新产品的市场潜力,包括家用诊断产品、消费者保健及医学营养产品等。
执行董事严振亮提到,除了研发非专利药并自行生产外,公司会采用引进授权的方式引入新产品,此举可令公司在获得增长的同时,亦不会加重生产负担,令成本获得更好的控制。公司在引进授权时,会选择毛利率达50%的药品,强调只会做市场少有的药品。
在品牌成药方面,严氏指保济丸在2019财年录逾10%的销售增长,但对此表现仍不感满意,希望能在未来一个财年加强国内销售。而在发展国内市场时,会与股东云南白药合作。至於旗下药品每年都会跟随通胀加价5至8%,加价时间则不定。(jc/a)
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.